America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 299.12 Thousand USD | -11.01% |
| 2022 | 336.14 Thousand USD | -46.05% |
| 2021 | 623.01 Thousand USD | 15899.44% |
| 2020 | 3894.00 USD | 3717.65% |
| 2019 | 102.00 USD | -99.22% |
| 2018 | 13.09 Thousand USD | 233.41% |
| 2017 | 3927.00 USD | -98.43% |
| 2016 | 249.46 Thousand USD | 927.6% |
| 2015 | 24.27 Thousand USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 20.09 Thousand USD | 3084.79% |
| 2012 | 631.00 USD | -90.62% |
| 2011 | 6725.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 333.39 Thousand USD | 3.02% |
| 2024 Q1 | 276.91 Thousand USD | -7.43% |
| 2024 Q2 | 323.61 Thousand USD | 16.86% |
| 2023 Q3 | 308.78 Thousand USD | -5.29% |
| 2023 FY | 299.12 Thousand USD | -11.01% |
| 2023 Q4 | 299.12 Thousand USD | -3.13% |
| 2023 Q1 | 354.18 Thousand USD | 5.37% |
| 2023 Q2 | 326.04 Thousand USD | -7.94% |
| 2022 Q3 | 467.18 Thousand USD | -22.64% |
| 2022 FY | 336.14 Thousand USD | -46.05% |
| 2022 Q4 | 336.14 Thousand USD | -28.05% |
| 2022 Q2 | 603.9 Thousand USD | 22.95% |
| 2022 Q1 | 491.17 Thousand USD | -21.16% |
| 2021 Q3 | 175.55 Thousand USD | -52.42% |
| 2021 Q2 | 368.93 Thousand USD | 9465.44% |
| 2021 Q4 | 623.01 Thousand USD | 254.89% |
| 2021 FY | 623.01 Thousand USD | 15899.44% |
| 2021 Q1 | 3857.00 USD | -0.95% |
| 2020 Q1 | 47.00 USD | -53.92% |
| 2020 Q2 | 147.00 USD | 212.77% |
| 2020 Q3 | 84.00 USD | -42.86% |
| 2020 FY | 3894.00 USD | 3717.65% |
| 2020 Q4 | 3894.00 USD | 4535.71% |
| 2019 Q1 | 12.07 Thousand USD | -7.74% |
| 2019 FY | 102.00 USD | -99.22% |
| 2019 Q3 | 198.00 USD | 45.59% |
| 2019 Q4 | 102.00 USD | -48.48% |
| 2019 Q2 | 136.00 USD | -98.87% |
| 2018 Q1 | 3480.00 USD | -11.38% |
| 2018 Q3 | 1482.00 USD | 72.33% |
| 2018 FY | 13.09 Thousand USD | 233.41% |
| 2018 Q4 | 13.09 Thousand USD | 783.47% |
| 2018 Q2 | 860.00 USD | -75.29% |
| 2017 Q2 | 77.64 Thousand USD | -69.46% |
| 2017 FY | 3927.00 USD | -98.43% |
| 2017 Q4 | 3927.00 USD | 1213.38% |
| 2017 Q3 | 299.00 USD | -99.61% |
| 2017 Q1 | 254.26 Thousand USD | 1.93% |
| 2016 Q2 | 412.22 Thousand USD | -25.2% |
| 2016 Q3 | 200.12 Thousand USD | -51.45% |
| 2016 Q4 | 249.46 Thousand USD | 24.65% |
| 2016 Q1 | 551.13 Thousand USD | 2170.29% |
| 2016 FY | 249.46 Thousand USD | 927.6% |
| 2015 Q4 | 24.27 Thousand USD | -61.46% |
| 2015 Q2 | 39.57 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | 24.27 Thousand USD | 0.0% |
| 2015 Q3 | 62.98 Thousand USD | 59.16% |
| 2014 Q2 | - USD | -100.0% |
| 2014 Q1 | 93.85 Thousand USD | 367.02% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2013 Q2 | 5426.00 USD | -65.17% |
| 2013 Q4 | 20.09 Thousand USD | -64.04% |
| 2013 FY | 20.09 Thousand USD | 3084.79% |
| 2013 Q1 | 15.57 Thousand USD | 2368.94% |
| 2013 Q3 | 55.88 Thousand USD | 929.86% |
| 2012 Q4 | 631.00 USD | 378.03% |
| 2012 Q3 | 132.00 USD | 0.0% |
| 2012 FY | 631.00 USD | -90.62% |
| 2011 FY | 6725.00 USD | 0.0% |
| 2011 Q4 | 6725.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 94.785% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 97.964% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 99.042% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 90.71% |
| Better Therapeutics, Inc. | 22.94 Million USD | 98.696% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 98.957% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 91.974% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 98.544% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 98.584% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 99.536% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | 87.291% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 99.579% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 98.856% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -293.627% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 97.542% |
| Molecular Templates, Inc. | 35.38 Million USD | 99.155% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | 93.157% |
| NexImmune, Inc. | 8.59 Million USD | 96.519% |
| Orgenesis Inc. | 14.55 Million USD | 97.944% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 97.465% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -139.989% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 94.734% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | 23.743% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.937% |
| Statera Biopharma, Inc. | 21.16 Million USD | 98.587% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 97.04% |
| Trevena, Inc. | 40.6 Million USD | 99.263% |
| Vaxxinity, Inc. | 44.35 Million USD | 99.326% |
| Vaccinex, Inc. | 3.63 Million USD | 91.762% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -654.31% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 99.472% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | 46.172% |